PMID- 29137078
OWN - NLM
STAT- MEDLINE
DCOM- 20171130
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 45
DP  - 2017 Nov
TI  - Successful treatment of ovarian cancer with apatinib combined with chemotherapy: 
      A case report.
PG  - e8570
LID - 10.1097/MD.0000000000008570 [doi]
LID - e8570
AB  - RATIONALE: The standard treatment for ovarian cancer is chemotherapy with 2 drugs 
      (taxanes and platinum drugs). However, the traditional combination of the 2 drugs 
      has many adverse effects (AEs) and the cancer cells will quickly become resistant 
      to the drugs. Apatinib is a small-molecule antiangiogenic agent which has shown 
      promising therapeutic effects against diverse tumor types, but it still remains 
      unknown whether apatinib has an antitumor effect in patients with ovarian cancer. 
      Herein, we present a successfully treated case of ovarian cancer using 
      chemotherapy and apatinib, in order to demonstrate the effectiveness of this new 
      combined regimen in ovarian cancer. PATIENTS CONCERNS: A 51-year-old Chinese 
      woman presented with ovarian cancer >4.5 years. The disease and the cancer 
      antigen 125 (CA-125) had been controlled well by surgical treatment and following 
      chemotherapy. However, the drugs could not control the disease anymore as the 
      CA-125 level was significantly increasing. DIAGNOSIS: Ovarian cancer. 
      INTERVENTIONS: The patient was treated with apatinib combined with epirubicin. 
      Apatinib was administered orally, at an initial daily dose of 500 mg, and was 
      then reduced to 250 mg qd after the appearance of intolerable hand-foot syndrome 
      (HFS) and oral ulcer. Then, the oral ulcer disappeared and the HFS was controlled 
      by dose adjustment, oral vitamin B6, and hand cream application. OUTCOMES: The 
      CA-125 reverted to the normal value after treatment with the new regimen. 
      Magnetic resonance imaging showed that the original tumor lesions had 
      disappeared. Apatinib monotherapy as maintenance therapy was then used to 
      successfully control the cancer with a complete response. Our study is the first, 
      to our knowledge, to report the therapeutic effects of apatinib and epirubicin on 
      ovarian cancer. LESSONS: Apatinib combined with chemotherapy and apatinib 
      monotherapy as maintenance therapy could be a new therapeutic strategy for 
      ovarian cancer, especially adenocarcinomas.
FAU - Zhang, Mingzi
AU  - Zhang M
AD  - Department of Pharmacy, Shenzhen Traditional Chinese Medicine Hospital Department 
      of Internal Medicine-Oncology, Second Affiliated Hospital of Jinan University, 
      Shenzhen People's Hospital, Shenzhen, Guangdong, People's Republic of China.
FAU - Tian, Zhongkai
AU  - Tian Z
FAU - Sun, Yehong
AU  - Sun Y
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (CA-125 Antigen)
RN  - 0 (Pyridines)
RN  - 3Z8479ZZ5X (Epirubicin)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - CA-125 Antigen/drug effects
MH  - Epirubicin/*administration & dosage
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Ovarian Neoplasms/*drug therapy/immunology
MH  - Pyridines/*administration & dosage
MH  - Treatment Outcome
PMC - PMC5690771
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2017/11/16 06:00
MHDA- 2017/12/01 06:00
PMCR- 2017/11/10
CRDT- 2017/11/16 06:00
PHST- 2017/11/16 06:00 [entrez]
PHST- 2017/11/16 06:00 [pubmed]
PHST- 2017/12/01 06:00 [medline]
PHST- 2017/11/10 00:00 [pmc-release]
AID - 00005792-201711100-00074 [pii]
AID - MD-D-17-04612 [pii]
AID - 10.1097/MD.0000000000008570 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Nov;96(45):e8570. doi: 10.1097/MD.0000000000008570.